List of Excipients in Branded Drug PERPHENAZINE

Generic Drugs Containing PERPHENAZINE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	perphenazine	0378-5350	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	perphenazine	0378-5350	HYDROXYPROPYL CELLULOSE
Mylan Pharmaceuticals Inc	perphenazine	0378-5350	HYPROMELLOSE
Mylan Pharmaceuticals Inc	perphenazine	0378-5350	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	perphenazine	0378-5350	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	perphenazine	0378-5350	POLYETHYLENE GLYCOL
Mylan Pharmaceuticals Inc	perphenazine	0378-5350	POLYSORBATE 80

What are the Most Frequently-Used Excipients in PERPHENAZINE?

# Of NDCs	Excipient
2	ACETONE
2	CALCIUM CARBONATE
2	CARNAUBA WAX
62	CELLULOSE, MICROCRYSTALLINE
2	DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER
18	FERRIC OXIDE YELLOW
20	FERROSOFERRIC OXIDE

Perphenazine Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Perphenazine is an established, low-cost phenothiazine antipsychotic with limited branded competition, no meaningful remaining composition-of-matter exclusivity, and a fragmented generic market. The strongest commercial opportunities are not conventional tablet replication. They are differentiated oral products that improve administration, dosing flexibility, adherence, and supply reliability while preserving bioequivalence and avoiding excipient-driven tolerability problems.

The most practical product concepts are:

1. A low-cost, robust immediate-release tablet portfolio covering 2 mg, 4 mg, 8 mg, and 16 mg.
2. An orally disintegrating tablet for patients with swallowing difficulty or adherence concerns.
3. A low-volume oral solution or concentrate for institutional and geriatric use.
4. A dose-flexible multiparticulate or liquid product, subject to FDA pathway and bioequivalence requirements.
5. A supply-secure, globally sourced generic using a simple excipient system with low manufacturing risk.

What is perphenazine and where is the commercial demand?

Perphenazine is a piperazine-substituted phenothiazine indicated for the management of schizophrenia and severe nausea and vomiting in adults. It is marketed primarily as an oral immediate-release tablet. The reference product, Trilafon, is no longer the principal commercial driver in the U.S.; generic perphenazine products supply the market.

Attribute	Perphenazine
Active ingredient	Perphenazine
Therapeutic class	Typical antipsychotic; phenothiazine
Primary U.S. dosage form	Immediate-release oral tablet
Common strengths	2 mg, 4 mg, 8 mg, 16 mg
Main indications	Schizophrenia; severe nausea and vomiting
U.S. reference brand	Trilafon
Regulatory status	FDA-approved conventional drug product
Generic status	Multiple generic products
Biosimilar relevance	None
Main commercial buyers	Retail pharmacies, hospitals, long-term-care facilities, wholesalers
Main product risks	Sedation, extrapyramidal symptoms, orthostatic hypotension, anticholinergic effects, excipient intolerance

Perphenazine is used in a mature market where procurement price, product availability, dosage coverage, and pharmacy substitution are more important than brand recognition. The product’s clinical use is constrained by the availability of newer antipsychotics and by the adverse-effect profile of typical phenothiazines.

The strongest demand is likely to come from long-term-care facilities, psychiatric institutions, hospital formularies, and patients stabilized on an established regimen. These buyers value continuity of supply and multiple strengths more than premium packaging or extensive patient-support programs.

What excipients are used in perphenazine tablets?

FDA labeling for generic perphenazine tablets identifies conventional tablet excipients, although the exact formulation varies by manufacturer and strength. Common excipient classes include lactose or another diluent, starch, povidone or another binder, magnesium stearate, and coloring agents. DailyMed listings must be reviewed product by product because inactive ingredients differ among manufacturers.[1]

Functional excipient requirements

Formulation function	Suitable excipient classes	Strategic objective
Dilution and tablet mass	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Support low-dose uniformity and compression
Binding	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improve mechanical strength
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Maintain rapid immediate release
Lubrication	Magnesium stearate, sodium stearyl fumarate	Prevent sticking and improve ejection
Glidancy	Colloidal silicon dioxide	Improve powder flow
Coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Improve swallowability, appearance, and light protection
Taste masking	Ion-exchange resins, polymer coatings, flavors, sweeteners	Support liquid or orally disintegrating formats
Suspension stabilization	Xanthan gum, hypromellose, cellulose derivatives	Maintain dose uniformity in liquid products
Preservation	Benzoates, sorbates, parabens, or other approved systems	Control microbial growth in multidose liquids

Perphenazine is a low-dose active pharmaceutical ingredient in the 2 mg and 4 mg strengths. Content uniformity, blend segregation, and powder flow are therefore important. A direct-compression formulation can reduce process complexity, but a wet-granulation process may provide better content uniformity and compressibility when the active has poor flow or low loading.

What is the best excipient strategy for an immediate-release perphenazine tablet?

The best base strategy is a conservative, conventional formulation using excipients with broad FDA Inactive Ingredient Database precedent and extensive supplier coverage.

A practical immediate-release platform would use:

• Microcrystalline cellulose or lactose as the principal diluent.
• Pregelatinized starch or povidone as a binder.
• Crospovidone or croscarmellose sodium as the primary disintegrant.
• Colloidal silicon dioxide for flow control.
• Magnesium stearate at the lowest effective concentration.
• A film coat based on hypromellose and polyethylene glycol where coating is needed.

The formulation should target rapid disintegration without creating excessive friability. A disintegrant system based on crospovidone is commercially attractive because it supports rapid water uptake and is widely used in immediate-release products. Croscarmellose sodium can also be effective but may require tighter control of compression force and moisture.

Lactose versus lactose-free platforms

Lactose is economical and widely accepted, but it creates avoidable restrictions for patients with lactose intolerance and for certain institutional buyers. A lactose-free platform based on microcrystalline cellulose, mannitol, or dibasic calcium phosphate may provide a meaningful procurement advantage.

Mannitol is attractive for orally disintegrating and chewable products because of its cooling mouthfeel and lower hygroscopicity than some polyols. It is more expensive than lactose and may require a stronger binder system.

Microcrystalline cellulose is a strong choice for a standard tablet but can produce a bulky tablet at low active loading. Dibasic calcium phosphate improves tablet density and hardness but may complicate dissolution if overused.

Colorants and light protection

Perphenazine products commonly use strength differentiation through tablet color, imprinting, or coating. Color systems should be selected with attention to:

• FDA certification requirements for color additives.
• Global restrictions on titanium dioxide.
• Patient sensitivity to dyes.
• Manufacturing consistency across strengths.
• Photostability of the active ingredient and finished product.

A dye-free, imprint-based product may reduce regulatory and sourcing risk. If multiple strengths are sold, visual differentiation remains important for medication-error prevention.

What formulation patents protect perphenazine products?

Perphenazine has no commercially significant remaining composition-of-matter patent barrier in the United States. The original drug was approved decades ago, and the core active ingredient is well beyond the ordinary patent term.

Potential intellectual-property exposure is more likely to arise from:

• A novel orally disintegrating formulation.
• A controlled-release delivery system.
• A taste-masked liquid or multiparticulate product.
• A specific polymorph, salt, particle-size distribution, or manufacturing process.
• A combination product.
• A method-of-use claim directed to a distinct patient population.

No major active innovator patent estate is associated with the conventional perphenazine immediate-release tablet market in the way seen for recently approved branded drugs. Any proposed product should still be screened against live U.S. and international patent databases before launch. Conventional excipient substitutions ordinarily do not create meaningful freedom-to-operate concerns unless they are claimed as part of a specific protected dosage form.

Orange Book and Paragraph IV status

The FDA Orange Book is relevant for listed perphenazine reference and generic products, but the key commercial point is that the market is already genericized. A new conventional tablet would generally be an ANDA product rather than a Paragraph IV challenger to a meaningful active patent barrier.

A Paragraph IV filing could become relevant if a third party later obtained an unexpired formulation or method-of-use patent covering a differentiated perphenazine product. That scenario would not normally block a standard generic tablet unless the patent claims the product or an unavoidable approved use.

When does perphenazine lose exclusivity?

Perphenazine lost practical market exclusivity decades ago. The U.S. reference product was approved in the 1950s, and the active ingredient’s original patent protection expired long before the current generic market.

Exclusivity category	Perphenazine position
New chemical entity exclusivity	Expired
Composition-of-matter patent	Expired
Reference-product exclusivity	Expired
Pediatric exclusivity	No material current barrier identified
Orphan exclusivity	Not applicable to the conventional product
Generic competition	Established
Biosimilar exclusivity	Not applicable

The relevant launch question is therefore not whether generic entry is permitted. It is whether a new supplier can obtain approval, maintain adequate quality, and compete profitably in a low-price market.

What FDA regulatory pathway applies to new perphenazine products?

A conventional immediate-release tablet that matches an approved reference product would normally proceed through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence and comply with current good manufacturing practice requirements.[2]

A novel dosage form may require a 505(b)(2) application. This pathway is more relevant to:

• Orally disintegrating tablets.
• Oral solutions or concentrates.
• Modified-release products.
• New routes of administration.
• Products with a new clinical use or dosing approach.

A 505(b)(2) product may obtain labeling or formulation differentiation, but it carries greater development cost and may trigger clinical, pharmacokinetic, or bridging requirements. The commercial case must support that added burden.

Which excipient opportunities have the strongest commercial potential?

Orally disintegrating tablets

An orally disintegrating tablet could target patients who have difficulty swallowing conventional tablets, including older adults and patients in psychiatric or long-term-care settings. The product should prioritize:

• Fast disintegration.
• Low friability.
• Minimal bitter taste.
• Low moisture sensitivity.
• Packaging that limits humidity exposure.
• Compatibility with dose strengths used in routine titration.

A mannitol-based matrix with crospovidone and a taste-masking approach is a plausible development platform. Perphenazine’s pharmacological potency means that even a small tablet can deliver the required dose, but taste masking remains important because the active may be unpleasant when dispersed in the mouth.

The commercial advantage would be strongest if the product offers a clear administration benefit rather than simply a different excipient profile.

Oral solution or concentrate

A liquid formulation could improve dose flexibility and administration to patients who cannot swallow tablets. It would also support institutional use and titration.

Key development problems include:

• Low aqueous solubility or pH-dependent solubility.
• Chemical stability.
• Adsorption to packaging.
• Dose uniformity after storage.
• Preservative effectiveness.
• Palatability.
• Avoidance of alcohol if clinically or commercially undesirable.

A solubilized liquid may require pH adjustment, cosolvents, surfactants, or complexing agents. Those excipients can alter tolerability and may complicate pediatric or geriatric positioning. A suspension may be easier to develop than a true solution but requires validated redispersibility and shake instructions.

A unit-dose cup or oral syringe presentation could reduce dosing errors. The market may be smaller than the tablet market, but competition is often less dense.

Sprinkle or multiparticulate formulation

A sprinkle product could allow administration with soft food. Multiparticulates can provide dose flexibility and taste masking without requiring a large tablet.

This approach creates manufacturing and regulatory demands involving:

• Uniform drug loading across particles.
• Coating integrity.
• Food compatibility.
• Stability after opening.
• Dose recovery from capsules or sachets.
• Demonstration that chewing does not alter exposure.

The opportunity is commercially credible but more complex than an orally disintegrating tablet.

Modified-release perphenazine

A controlled-release product could reduce dosing frequency and smooth plasma exposure. It is also the highest-risk formulation concept because perphenazine has longstanding clinical use as an immediate-release product and any modified-release claim would need a clear pharmacokinetic and clinical rationale.

A modified-release product could require:

• Extended-release bioequivalence studies.
• Food-effect assessment.
• Dose-dumping evaluation.
• Abuse and misuse assessment where relevant.
• Clinical justification for the new exposure profile.

The market opportunity is uncertain because generic tablets are inexpensive and clinicians may not view reduced dosing frequency as sufficient to justify a premium.

How strong is the patent estate for perphenazine?

The conventional perphenazine patent estate is weak from an exclusivity perspective and strong from a freedom-to-compete perspective. The active ingredient is old, generic competition is established, and conventional excipient systems are widely available.

Estate component	Strength	Commercial implication
Active ingredient protection	Very low	No barrier to standard generic entry
Conventional tablet formulation	Very low	Easy design-around and supplier substitution
Novel ODT formulation	Potentially moderate	Protection depends on specific claim scope
Liquid formulation	Potentially moderate	Stability and taste-masking claims may be protectable
Modified release	Potentially moderate to strong	Higher development and litigation risk
Manufacturing process	Low to moderate	Claims must be technically narrow and enforceable
Method of use	Variable	Depends on indication and claim validity
Trade secrets	Moderate operational value	Process controls and taste masking may matter more than patents

The strongest defensible position would likely combine a differentiated dosage form with manufacturing know-how, device or packaging differentiation, and supply-chain control.

What generic launch risks exist for perphenazine?

Generic launch risk is primarily commercial and operational rather than patent-driven.

Price erosion

Perphenazine is a mature generic. A new entrant should expect price competition, especially for the 4 mg and 8 mg strengths. The 2 mg and 16 mg strengths may have different supply dynamics because demand is more concentrated and some suppliers may not maintain the full portfolio.

Manufacturing scale

The active ingredient is inexpensive relative to development and regulatory costs. A manufacturer needs efficient tablet production, reliable analytical methods, and sufficient annual volume to absorb:

• ANDA development.
• Stability studies.
• Artwork and packaging.
• Pharmacovigilance.
• FDA inspection readiness.
• Product liability and recall reserves.

Supply continuity

Institutional buyers may prefer suppliers with a record of uninterrupted availability. A dual-source strategy for the active ingredient and critical excipients can reduce shortage exposure.

Product liability and clinical labeling

Perphenazine labeling includes serious adverse reactions associated with antipsychotic therapy, including tardive dyskinesia, neuroleptic malignant syndrome, and increased mortality risk in elderly patients with dementia-related psychosis.[3] A formulation that materially changes exposure or administration could create additional pharmacovigilance obligations.

Which companies are challenging perphenazine?

Perphenazine is already challenged commercially by generic manufacturers rather than by a concentrated patent-litigation campaign. The market includes or has included multiple U.S. generic suppliers and distributors, with availability varying by strength and time.

No meaningful current biosimilar competition exists because perphenazine is a small-molecule drug. The competitive landscape is defined by:

• ANDA holders.
• Contract manufacturers.
• Repackagers.
• Wholesalers.
• Hospital and long-term-care purchasing groups.

Live supplier participation should be confirmed through FDA Drugs@FDA, the Orange Book, DailyMed, and current wholesaler listings before making a launch or licensing decision.[1,4]

What licensing deals and commercial partnerships are relevant?

Perphenazine has limited licensing appeal as a conventional tablet because the molecule is old and the market is price-sensitive. Licensing value increases when the asset includes:

• A clinically meaningful new dosage form.
• A protected taste-masking platform.
• A ready-to-file 505(b)(2) package.
• A validated liquid or sprinkle technology.
• Exclusive regional manufacturing rights.
• Institutional distribution contracts.
• A supply agreement with a reliable API source.

A formulation company could license an ODT or liquid platform to an established generic manufacturer. The likely deal structure would emphasize milestone payments, manufacturing transfer, minimum annual volumes, and territory-based commercialization rather than a large upfront payment based solely on perphenazine sales.

How does perphenazine compare with competing antipsychotics?

Product	Patent and exclusivity profile	Formulation opportunity	Competitive position
Perphenazine	Long generic history; no meaningful core exclusivity	ODT, liquid, sprinkle, supply differentiation	Low-cost legacy therapy
Haloperidol	Mature generic market	Injectable, oral liquid, decanoate products	Strong institutional presence
Risperidone	Mature generic market with multiple dosage forms	ODT, liquid, long-acting injection	Broader modern use
Olanzapine	Mature generic market	ODT and standard tablets	Stronger commercial demand
Quetiapine	Mature generic market	Immediate- and extended-release	Larger market and broader use
Aripiprazole	Generic competition after branded exclusivity	ODT, liquid, long-acting injection	Higher-value modern antipsychotic segment

Perphenazine cannot generally compete on market size against risperidone, olanzapine, quetiapine, or aripiprazole. Its competitive advantages are low acquisition cost, established clinician familiarity, and availability across several tablet strengths.

What geographic opportunities exist?

The United States is attractive for a standard ANDA only if the applicant has a low-cost operating model and can secure stable distribution. Europe and other regulated markets may offer opportunities for:

• Lactose-free tablets.
• Dye-free products.
• Oral liquids.
• Institutional dosage forms.
• Local supply agreements.
• Products adapted to national reimbursement systems.

Patent risk is low in most major markets because the active ingredient is old. Regulatory requirements, reference-product selection, local bioequivalence rules, language requirements, and reimbursement pricing are more important than patent term.

Emerging markets may provide volume, but pricing pressure, registration requirements, local manufacturing rules, and tender-based procurement can reduce margin. A regional licensing model may be more effective than direct commercialization.

What revenue exposure and investment case apply to perphenazine?

Perphenazine revenue is difficult to attribute to a single company because the market is supplied by multiple generic manufacturers and private-label distributors. The commercial case should be based on unit volume, net price, manufacturing cost, and supply reliability rather than branded sales forecasts.

A standard tablet launch is a scale-and-efficiency opportunity. A differentiated dosage form is a niche opportunity with higher gross-margin potential but greater regulatory and technical risk.

Strategy	Development cost	Patent value	Margin potential	Main risk
Standard tablet	Low to moderate	Low	Low	Price erosion
Lactose-free or dye-free tablet	Low to moderate	Low	Low to moderate	Limited willingness to pay
ODT	Moderate	Moderate	Moderate	Taste, moisture, bioequivalence
Oral solution	Moderate	Moderate	Moderate	Stability and palatability
Sprinkle multiparticulate	Moderate to high	Moderate	Moderate to high	Manufacturing complexity
Modified release	High	Moderate to high	Potentially high	Clinical and regulatory burden

Key Takeaways

• Perphenazine has no meaningful remaining core patent or exclusivity barrier in the conventional generic market.
• The standard immediate-release tablet is the lowest-risk product but offers limited pricing power.
• Excipient selection should prioritize content uniformity, rapid disintegration, low moisture sensitivity, and broad FDA precedent.
• A lactose-free or dye-free formulation may create modest procurement differentiation.
• Orally disintegrating tablets and oral liquids offer the clearest formulation-led opportunities.
• Modified-release development has the highest technical and regulatory burden and requires a strong clinical rationale.
• Patent value is more likely to arise from a novel dosage form, taste-masking system, manufacturing process, or packaging configuration than from the active ingredient.
• Biosimilar risk is irrelevant because perphenazine is a small molecule.
• Commercial success depends on supply continuity, multi-strength coverage, institutional distribution, and manufacturing cost control.
• A conventional product should be pursued as a low-cost generic platform; a differentiated product should be pursued through a 505(b)(2) and lifecycle-management strategy.

FAQs

Is perphenazine still protected by patents?

The original active-ingredient and reference-product exclusivity periods expired decades ago. Conventional perphenazine tablets are not protected by a meaningful active patent barrier.

Can a company launch a perphenazine orally disintegrating tablet?

Yes. An ODT could be developed as a differentiated dosage form, but the regulatory pathway, bioequivalence requirements, taste masking, moisture control, and product-specific patent analysis would determine launch feasibility.

Which excipient is best for perphenazine taste masking?

No single excipient is universally optimal. A mannitol-based ODT with a polymeric coating, ion-exchange resin, or other validated taste-masking system is a practical development direction, subject to dissolution and exposure testing.

Is perphenazine suitable for a liquid formulation?

Yes, but the formulation must address solubility, chemical stability, preservative effectiveness, redispersibility if suspended, palatability, and dose uniformity. A suspension may be more practical than a true solution.

Does perphenazine have biosimilar competition?

No. Perphenazine is a synthetic small-molecule drug. Competitive products are generics approved through the ANDA pathway, not biosimilars.

References

1. National Library of Medicine. (n.d.). DailyMed: Perphenazine tablet labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (n.d.). Perphenazine prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book